CHONGQING, China, June 14, 2026 /PRNewswire/ -- At the 28th Chongqing International Auto Exhibition, Changan Group showcased its full brand lineup including CHANGAN NEVO,...
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...
NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...
NEW YORK and ATHENS, Greece, June 13, 2026 /PRNewswire/ -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the US biopharma...
GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...
BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1
TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...
Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --
An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026
VALENCIA, Calif., June 12, 2026 /PRNewswire/ -- HASA Inc. (www.hasa.com), a leading producer and distributor of high-quality water treatment solutions, today announced the acquisition of Bio–Dex Laboratories,...